SCA
NBIX icon

Spearhead Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Spearhead Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,020
Closed -$342K – 217
2021
Q4 		$342K Buy
4,020
+48
+1% +$4.42K 0.04% 135
2021
Q3 		$381K Sell
3,972
-28
-0.7% -$2.65K 0.05% 129
2021
Q2 		$389K Buy
4,000
+595
+17% +$57K 0.05% 149
2021
Q1 		$331K Buy
3,405
+1,077
+46% +$113K 0.05% 140
2020
Q4 		$223K Buy
2,328
+142
+6% +$13.7K 0.04% 165
2020
Q3 		$210K Buy
2,186
+144
+7% +$16.7K 0.04% 178
2020
Q2 		$249K Buy
+2,042
New +$226K 0.05% 129

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Spearhead Capital Advisors's NBIX Position: Q1 2022 in Review

Spearhead Capital Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2022, closing a stake of 4,020 shares — an estimated $342K sold.

Spearhead Capital Advisors first reported a position in NBIX in Q2 2020 and held it in 7 quarters. The position peaked at $389K in Q2 2021. 426 funds tracked by Wall St. Rank hold NBIX as of Q1 2022.

  • Spearhead Capital Advisors reported no remaining Neurocrine Biosciences position as of Q1 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 4,020 Neurocrine Biosciences shares in Q1 2022, an estimated $342K.
  • Spearhead Capital Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 7 quarters.
  • Spearhead Capital Advisors's Neurocrine Biosciences position peaked at $389K in Q2 2021.
  • 426 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2022.

Based on Spearhead Capital Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.